Literature DB >> 27357015

Cancer: Bivalent mTOR inhibitors - the next generation.

Alexandra Flemming.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27357015     DOI： 10.1038/nrd.2016.134

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

Authors:  Vanessa S Rodrik-Outmezguine; Masanori Okaniwa; Zhan Yao; Chris J Novotny; Claire McWhirter; Arpitha Banaji; Helen Won; Wai Wong; Mike Berger; Elisa de Stanchina; Derek G Barratt; Sabina Cosulich; Teresa Klinowska; Neal Rosen; Kevan M Shokat
Journal:  Nature       Date:  2016-05-18       Impact factor: 49.962
  1 in total
  3 in total

1.  Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.

Authors:  Weijian Sun; Yongdong Yi; Guojun Xia; Yaxin Zhao; Yaojun Yu; Liyi Li; Chunya Hua; Bin He; Beng Yang; Chengyang Yu; Chenmin Ye; Fuyang Tu; Canjin Chen; Xiaoying Xu; Zhiqiang Zheng; Wenqian Wang; Xian Shen
Journal:  Mol Ther       Date:  2019-02-15       Impact factor: 11.454

2.  Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation.

Authors:  Fuchun Yang; Shaogang Sun; Chenran Wang; Michael Haas; Syn Yeo; Jun-Lin Guan
Journal:  Br J Cancer       Date:  2020-04-27       Impact factor: 7.640

3.  Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.

Authors:  Shraddha Parate; Vikas Kumar; Gihwan Lee; Shailima Rampogu; Jong Chan Hong; Keun Woo Lee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.